Tresiba Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising prevalence of diabetes globally, increased diagnosis of type 2 diabetes, expansion of insulin therapy usage, growing awareness of long-acting insulin benefits, availability of advanced insulin formulations.

The growth in the forecast period can be attributed to increasing adoption of personalized diabetes treatment plans, rising use of digital diabetes management tools, expansion of insulin access in emerging markets, growing focus on treatment adherence improvement, increasing investments in next-generation insulin products. Major trends in the forecast period include increasing adoption of ultra-long acting insulin therapies, rising preference for once-daily insulin regimens, growing focus on glycemic stability management, expansion of patient-centric diabetes care models, enhanced integration with digital glucose monitoring.

The increasing prevalence of diabetes is expected to drive the growth of the Tresiba market in the coming years. Diabetes is a chronic medical condition in which the body is unable to properly regulate blood sugar (glucose) levels. The rising prevalence of diabetes is attributed to factors such as sedentary lifestyles, unhealthy dietary habits, increasing obesity rates, aging populations, and genetic predisposition. Tresiba benefits patients by offering improved glycemic control, reducing the risk of hypoglycemia, and providing flexible dosing options, which enhance treatment adherence and overall diabetes management outcomes. For example, according to the Institute for Health Metrics and Evaluation, a US-based public health research institute, over half a billion people globally were living with diabetes in 2023, and this number is expected to more than double to 1.3 billion by 2050. Therefore, the increasing prevalence of diabetes is driving growth in the Tresiba market.

The rising prevalence of obesity is also expected to support the growth of the Tresiba market. Obesity is a medical condition characterized by excessive body fat that negatively affects health, commonly measured using body mass index (BMI), the ratio of weight to height. The increase in obesity is driven by changes in global food systems and dietary habits, including higher consumption of ultra-processed foods, sedentary lifestyles, and economic factors that make unhealthy food choices more accessible. Tresiba aids obese patients by providing long-acting insulin that improves glycemic control, lowers the risk of hypoglycemia, and supports weight management through flexible dosing. For instance, according to the Office for Health Improvement & Disparities, a UK government department, between 2022 and 2023 approximately 64% of adults aged 18 and older in England were classified as overweight or obese. Consequently, the rise in obesity is contributing to the growth of the Tresiba market.

The growing geriatric population is anticipated to drive the expansion of the Tresiba market in the coming years. The geriatric population consists of individuals generally aged 65 years and older, who are often at higher risk for age-related health issues and may require specialized medical care. This population is increasing mainly due to rising life expectancy, as advancements in healthcare, nutrition, and disease management allow more people to live longer, leading to a larger proportion of older adults within the overall population. Tresiba supports the geriatric population by providing a stable, ultra-long-acting insulin profile that reduces the risk of hypoglycemia, ensuring safer and more consistent blood sugar control for older adults who are particularly vulnerable to low blood sugar events. For example, in February 2025, the World Health Organization, a Switzerland-based specialized agency, reported that the global population of individuals aged 60 years and above is projected to grow from 1.1 billion in 2023 to 1.4 billion by 2030. Thus, the expanding geriatric population is contributing to the growth of the Tresiba market.

Major companies operating in the tresiba market are Novo Nordisk A/S.

North America was the largest region in the tresiba market in 2025. The regions covered in the tresiba market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tresiba market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the tresiba market by raising costs of imported active pharmaceutical ingredients, biologic formulation inputs, prefilled pen components, and temperature-controlled packaging materials. Diabetes treatment providers in North America and Europe are most affected due to reliance on imported insulin production inputs, while Asia-Pacific faces pricing pressure on distribution and device components. These tariffs increase manufacturing and distribution costs, contributing to higher insulin prices. At the same time, they are encouraging local insulin production, regional filling and packaging facilities, and greater supply chain resilience for long-acting insulin therapies.

The tresiba market research report is one of a series of new reports that provides tresiba market statistics, including tresiba industry global market size, regional shares, competitors with a tresiba market share, detailed tresiba market segments, market trends and opportunities, and any further data you may need to thrive in the tresiba industry. This tresiba market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tresiba (insulin degludec) is a long-acting insulin used to manage diabetes mellitus in both adults and children. It helps regulate blood sugar levels in individuals with type 1 or type 2 diabetes by providing a steady release of insulin over an extended period.

The primary indications for Tresiba are type 1 diabetes and type 2 diabetes. Type 1 diabetes is a chronic autoimmune condition in which the immune system destroys insulin-producing beta cells in the pancreas, resulting in insufficient insulin production and elevated blood sugar levels. Tresiba is distributed through hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies, serving various patient groups, including adults, elderly patients, and children.

The tresiba market consists of sales of tresiba U-100, tresiba U-200, and pre-filled flextouch pen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.